Diethylstilbestrol

CAS No:
56-53-1 Category:
  • #LGM Pharma is a Diethylstilbestrol CAS# 56-53-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 56-53-1
  • AHFC code: 08:16.0
  • Synonyms: DES Diethylstilbesterol Diethylstilbestrol BP Diethylstilboesterol Dietilestilbestrol Percutatrine oestrogenique iscovesco Rcra waste number U089 trans-Diethylstilbesterol trans-Diethylstilbestrol trans-Diethylstilboesterol
  • ATC Code: G03CB02 G03CC05 L02AA01
  • Chemical Formula: C24H30N2O2
  • Molecular Weight: 268.3502
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB00255 (APRD00920, EXPT01164)
  • SMILES: CCC(=C(CC)C1=CC=C(O)C=C1)C1=CC=C(O)C=C1
  • InChl: RGLYKWWBQGJZGM-ISLYRVAYSA-N
  • PubChem: 448537
  • IUPAC: 4-[4-(4-hydroxyphenyl)hex-3-en-3-yl]phenol

Additional Details

Indication:
Used in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
Pharmacodynamics:
Diethylstilbestrol is a synthetic estrogen that was developed to supplement a woman's natural estrogen production. In 1971, the Food and Drug Administration (FDA) issued a Drug Bulletin advising physicians to stop prescribing DES to pregnant women because it was linked to a rare vaginal cancer in female offspring.
Mode of Action:
Estrogens diffuse into their target cells and interact with a protein receptor, the estrogen receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. The effect of Estrogen binding their receptors causes downstream increases the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).
Metabolism:
Hepatic.
Toxicity:
Symptoms of overdose include nausea and vomiting, and withdrawal bleeding may occur in females.
General Reference:
: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med. 1984 Nov 15;311(20):1281-6. Pubmed DIECKMANN WJ, DAVIS ME, RYNKIEWICZ LM, POTTINGER RE: Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol. 1953 Nov;66(5):1062-81. Pubmed Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21. Pubmed Kuchera LK: Postcoital contraception with diethylstilbestrol. JAMA. 1971 Oct 25;218(4):562-3. Pubmed Herbst AL, Ulfelder H, Poskanzer DC: Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971 Apr 15;284(15):878-81. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials

 

Related YouTube Videos